Sonic Healthcare (ASX: SHL) is an Australian-listed company in the Healthcare sector with a market capitalisation of $10.50B and the 70th-largest security on the ASX by market capitalisation. The SHL share price is $21.25, up 1.58% today and down 21.12% over the past 12 months. Shares have traded between $18.26 and $29.24 over the past 52 weeks. SHL trades on a price-to-earnings ratio of 10.67, below the Healthcare sector median of 10.89, and pays a trailing dividend yield of 2.79%. In its most recent reported period (ending 31 Dec 2025), Sonic Healthcare reported revenue of $5.41B and a net profit of $262.5M (4.8% margin).
About Sonic Healthcare Limited
Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory medicine and pathology testing, covering biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal diagnostics, toxicology, and other related functions. Furthermore, Sonic provides extensive radiology services, such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Its offerings also extend to primary care medical services, featuring general practice clinics, occupational health, specialized skin cancer clinics, after-hours GP services, IT solutions for general practices, and various community-based healthcare programs. Operating internationally, the company has a significant presence in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, and Belgium. Founded in 1934, Sonic Healthcare Limited is headquartered in Sydney, Australia.
